Section 29 (New Zealand) in United Arab Emirates

About Section 29 (New Zealand)

New Zealand's Medsafe pathway for unapproved medicines.

How Section 29 (New Zealand) works in United Arab Emirates

The UAE recognises a formal Named Patient / compassionate-use pathway via MOHAP and the Department of Health Abu Dhabi (DoH). Physicians apply on behalf of individual patients for drugs not registered in-country.

Patients in United Arab Emirates seeking access under Section 29 (New Zealand) typically follow this flow: a licensed physician in United Arab Emirates issues the prescription and clinical justification, the regulator reviews and authorises, and an authorised operator coordinates import.

Documents required in United Arab Emirates

• Physician prescription and clinical-justification letter.
• Patient identification and consent.
• Country-specific NPP/personal-import form.
• Hospital or clinic attestation where required.

Typical timeline

End-to-end 2-6 weeks in most tier 1 jurisdictions. Cellular and gene therapies may require additional ethics-committee review.

Start a request

Start a request under Section 29 (New Zealand) in United Arab Emirates